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Serotonin syndrome (SS) is a potentially life-threatening adverse drug effect 
that occurs after an overdose or combined administration of two or more drugs that 
increase the serotonin levels. In humans, SS is represented by a triad of symptoms 
including mental status changes, neuromuscular hyperactivity and autonomic 
dysfunction. The manifestations of the syndrome observed in rodents resemble the 
symptoms of SS in humans. Theoretically, SS can occur as a result of stimulation 
of any of the seven families of the serotonin receptors. However, most data support 
the involvement of 5-HT1A and 5-HT2A receptors. A number of studies indicate the 
effectiveness of 5-HT2 antagonists and GABA-ergic agents in the treatment of the 
hyperthermia and other symptoms of SS in rats. Therefore, animal models of SS 
may help to further elucidate the mechanism of its development and the possibilities 
for its treatment.
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1. Introduction
Serotonin syndrome is a drug-induced condition caused by medications that 
increase intrasynaptic serotonin levels. It is characterized by a triad of symptoms 
that includes neuromuscular hyperactivity, altered mental status and autonomic 
dysfunction.
The syndrome was first described in 1960 as “Indolamine syndrome” in patients 
on therapy with monoamine oxidase inhibitors (MAOIs) who develop symptoms of 
serotonin syndrome after taking tryptophan – a serotonin precursor [1]. Since then, 
the number of reported cases of serotonin syndrome has increased significantly. The 
medical community’s attention to serotonin syndrome was drawn in 1984 by the 
unusual death of 18-year-old Libby Zion in a New York City hospital, which may have 
been linked to the development of serotonin syndrome after concomitant use of an 
MAOI and opioid analgesic. The opioid analgesic pethidine was administered to the 
girl suffering from depression and taking the antidepressant phenelzine, which led to 
the development of a fatal serotonin syndrome [2, 3].
Of all serotonergic drugs, antidepressants are the most common cause of sero-
tonin syndrome, and recent data suggest that the most common drug combination 
associated with serotonin syndrome is that between selective serotonin reuptake 
Serotonin and the CNS - New Developments in Pharmacology and Therapeutics
2
inhibitors (SSRIs) and opioids [2]. As a relatively rare adverse drug reaction, the 
incidence of serotonin syndrome is difficult to be calculated during randomized 
controlled trials [4]. Moreover, it is estimated that over 85% of physicians are 
unaware of the condition [5]. The non-specific manifestation of the syndrome 
leads to its difficult recognition and underreporting, which further complicates 
the determination of its incidence. It is considered that serotonin syndrome occurs 
in 15% of patients who overdose on selective serotonin reuptake inhibitors. The 
actual incidence of serotonin syndrome is thought to be significantly higher than 
reported [6–8].
2. Molecular mechanism of serotonin syndrome development
Serotonin syndrome results from an increase in intrasynaptic serotonin levels 
caused by overstimulation of both central and peripheral serotonin receptors  
[9, 10]. Theoretically, serotonin syndrome can occur as a result of stimulation of 
any receptor of all seven serotonin receptor families [11]. However, the role of 
5-HT1A and 5-HT2A is most often mentioned [6, 7, 11, 12]. Moreover, the 5-HT2A 
receptor is thought to mediate the most serious consequences of the serotonin 
syndrome (Table 1).
Some authors suggest that the development of serotonin syndrome requires the 
accumulation of a critical amount of serotonin. However, studies show that this 
level of serotonin is probably different for each patient. Experimental studies in 
animal models of serotonin syndrome have shown that other neurotransmitters 
such as noradrenaline (NA), N-methyl-D-aspartate (NMDA), gamma-aminobutyric 
acid (GABA) and dopamine may also play a role in the development of serotonin 
syndrome but their role is not fully understood [6, 13].
It is shown that in serotonin syndrome CNS serotonin levels increase between 
40 and 140 times. At the same time, dopamine levels are increased 10 to 44 times 
[14, 15]. Other studies indicate overactivation of the noradrenergic system with 
a rise in NA levels up to 15.9 times in serotonin syndrome, but the cause remains 
unknown. Some authors explain this increase in NA levels with activation of 
5-HT2A receptors. This is supported by the fact that no significant increase in NA 
was observed with prior administration of ritanserin and pipamperone which act as 
antagonists of these receptors. On the other hand, there is evidence of the involve-
ment of 5-HT1A receptors, although the administration of 5-HT1A antagonists 
does not prevent the increase in NA levels [14, 15]. The degree of NA increase may 
Receptor Function related to serotonin toxicity
Type Subtype
5-HT1 5-HT1A neuronal inhibition, thermoregulation, hyperactivity associated with anxiety, 
hypoactivity associated with depression
5-HT1D locomotion, muscle tone
5-HT2 5-HT2A neuronal excitation, vasoconstriction, platelet aggregation
5-HT2B smooth muscle contraction
5-HT3 — nausea and vomiting
5-HT4 — increased GIT motility
5-HT = 5-hydroxytryptamine (serotonin); GIT = gastrointestinal tract.
Table 1. 
Serotonin receptors associated with the serotonin syndrome development [10–12].
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be related to the prognosis of serotonin syndrome, although it is not fully under-
stood. At the same time, some of the observed symptoms of autonomic instability 
may be due to an overactivated noradrenergic system [14].
3. Implicated drugs
Drugs and substances that increase serotonin levels are known as serotonergic, 
and a mechanism by which they do that are as follows:
• Increased serotonin synthesis
• Increased serotonin release
• Activation of serotonergic receptors
• Serotonin reuptake inhibition
• Inhibition of serotonin metabolism
The full list of all serotonergic substances is long, but antidepressants and, 



















Antidepressants: Bupropion, Nefazodone, Trazodone;
SNRIs (Venlafaxine, Desvenlafaxine, Duloxetine);
SSRIs (Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Citalopram, 
Escitalopram);
TCAs (Amitriptyline, Nortriptyline, Imipramine, Desipramine, Clomipramine, 
Amoxapine, Doxepin, Maprotiline, Trimipramine);
Opioids: Tramadol, Pethidine, Tapentadol, Levomethorphan, Levorphanol, 
Methadone, Pentazocine, Dextropropoxyphen, Fentanyl, Remifentanyl
OTC drugs: Dextromethorphan
Antiemetics: Ondansetron, Granisetron,
Herbal supplements: Hypericum perforatum (St. John’s wort)
Inhibition of serotonin 
metabolism
MAOIs: Tranylcypromine, Phenelzine, Isocarboxazid, Nialamid, Iproniazid, 
Pargyline, Clorgiline, Moclobemide, Toloxatone
Antibiotics: Linezolid
Dyes: Methylene blue
Triptans: Sumatriptan, Rizatriptan,, Zolmitriptan, Almotriptan, Eletriptan, 
Frovatriptan, Naratriptan
Anxiolytics: Buspirone
Herbal supplements: Hypericum perforatum (St. John’s wort)
Table 2. 
Implicated drugs [5–7, 16–19].
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substances with serotonergic activity include not only antidepressants and opioids 
but also a number of other drugs used in everyday medical practice – some antibi-
otics, antiemetics, anxiolytics, antipsychotics, as well as over-the-counter drugs 
(OTC), dietary supplements, some illicit drugs and more [5–7, 16–19].
Some of the antidepressants, opioids, and other drugs reported in the literature 
causing serotonin syndrome, as well as the mechanisms by which they increase 
serotonin levels are listed in Table 2.
4. Experimental serotonin syndrome
The term “serotonin syndrome” in animals was first used in 1979 by Hwang 
and Van Woert [20, 21]. Manifestation of serotonin toxicity has been described in 
various animal species, however, most literature data, respectively most studies, are 
available on the development of serotonin syndrome in mice and rats [20].
In contrast to humans, in whom the symptoms of serotonin syndrome are well 
defined, the literature describes a wide variety of manifestations and different 
combinations of responses characterizing the development of serotonin syndrome 
in rodents.
There is considerable heterogeneity in the animal models reported in the litera-
ture. The use of different assessment methods, different response sets and different 
scales in assessing the effects of increased serotonergic tone limits quantitative 
comparisons of laboratory results. In this regard, Haberzettl et al. [20] conducted a 
systematic literature review of the described models of serotonin syndrome in rats 
and mice and evaluated the observed behavioral and autonomic manifestations. 
Based on the frequency of behavioral manifestations, the team divides them into 
traditional and additional, distinguishing those that reliably characterize the devel-
opment of serotonin syndrome in rodents. The described behavioral and autonomic 
symptoms of serotonin syndrome in rats are presented in Table 3.
It is widely believed that 5-HT1A receptors mediate most behavioral manifesta-
tions of serotonin syndrome in rats [22, 23–31]. In support of this are studies 
demonstrating the induction of serotonin syndrome behaviors by the administra-
tion of 5-HT1A agonists [26, 32, 33] and the induction of a narrower spectrum of 
manifestations such as hind limb abduction, a Straub phenomenon and low body 
posture, from the partial 5-HT1A-agonist buspirone [31].
Other behavioral responses such as head weaving and wet dog shake, are medi-
ated by 5-HT2A receptors [22, 34–37]. For example, head weaving in rats induced 
by the administration of the non-selective MAO inhibitor phenelzine and the SSRI 
paroxetine was dose-dependently antagonized by 5-HT2 antagonists [35, 37]. In 
addition, head weaving caused by the administration of a 5-HT2A/2C agonist has been 
antagonized by the administration of a 5-HT2A antagonist, but not by a 5-HT2C/2B 
antagonist [38].
The analysis of Haberzettl et al. showed that the most common autonomic 
dysregulation manifestation observed in rats with serotonin syndrome is the change 
in the body temperature. The hyperthermic reaction observed is thought to be 
mainly related to the activation of 5-HT2A receptors [14, 39]. Experimental studies 
confirmed the involvement of 5-HT1A and 5-HT2A receptors in thermoregulation in 
rats. For example, blockade of 5-HT2 receptors by ketanserin or pirenperone causes 
a decrease in body temperature, while blockade of 5-HT1A receptors by pindolol 
results in an increase in body temperature [40].
Although not a mandatory manifestation of serotonin syndrome, hyperther-
mia is one of the leading causes of observed mortality in experimental serotonin 
syndrome. In both animals and humans, it is hyperthermia that mainly causes 
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complications. Such complications in humans could include seizures, rhabdomy-
olysis, myoglobinuria, metabolic acidosis, renal failure, acute respiratory distress 
syndrome, respiratory failure, disseminated intravascular coagulation (DIC 
syndrome), coma and death [6].
The manifestation of serotonin syndrome observed in rodents resembles the 
manifestation of serotonin syndrome in humans (Table 4). For example, neuro-
muscular manifestations such as tremor and muscle rigidity have been observed 
in both humans and rodents. Myoclonus, which is a clinical symptom of serotonin 
syndrome in humans, in rodents may manifest as head twitches and forepaw tread-
ing. The Straub phenomenon observed in rodents may refer to the muscle rigidity 
observed in humans [21]. According to autonomic dysregulation manifestation, 
changes in body temperature occur in both rodents and humans.
The most difficult to differentiate in animals is the third group of symptoms 
typical for the manifestation of serotonin syndrome in humans - mental status 
changes. However, hyperactivity and to some extent the hyperreactivity observed in 
rodents are associated with agitation observed in humans. Moreover, it is important 
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Symptoms and manifestations of serotonin syndrome in humans and rodents – Comparison.
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to note that the current criteria for diagnosing serotonin syndrome in humans, 
Hunter’s criteria, do not include as a mandatory diagnostic criterion changes in 
mental status, which confirms the validity and applicability of the animal model of 
serotonin syndrome [21].
Two classical models of serotonin syndrome in rats have been described in the 
literature induced by concomitant administration of serotonergic substances with 
different mechanisms of action: 5-HTP (100 mg/kg i.p.) - a precursor of serotonin 
and clorgyline (2 mg/kg i.p.) - selective MAO-A inhibitor [14] and fluoxetine 
(10 mg/kg i.p.) - a selective serotonin reuptake inhibitor and tranylcypromine 
(3.5 mg/kg, i.p.) - a non-selective MAO inhibitor [12].
5.  Effect of GABA-ergic drugs on experimental models of serotonin 
syndrome
Many central neurotransmitters, such as serotonin, norepinephrine, dopamine, 
acetylcholine, GABA and glutamate, are involved in the thermoregulation. GABA is 
a major central inhibitory neurotransmitter involved in thermoregulatory processes. 
The role of GABA as a thermoregulatory neurotransmitter or modulator is suggested 
by the good distribution of the mediator in the hypothalamus, confirmed by auto-
radiographic and immunohistochemical studies [41–43] and its central action. In 
addition, GABA-ergic neurons, as well as postsynaptic GABAA-ergic receptors have 
been identified in PO/AH (preoptic area/anterior hypothalamus) [44–46].
Potentiation of the central inhibitory effect of GABA is achieved by several 
different mechanisms, including allosteric modulation of GABA receptors (benzo-
diazepines, barbiturates, Z-hypnotics, propofol and fospropofol), direct GABA- or 
GABA-receptor agonist action (respectively muscimol, baclofen), increased 
synthesis of GABA (e.g., gabapentin, pregabalin, sodium valproate), inhibition of 
enzymatic degradation of GABA (e.g., vigabatrin, sodium valproate) and inhibition 
of neuronal or glial uptake of GABA (e.g., tiagabine).
Benzodiazepines mediate their pharmacological effects by enhancing the 
inhibitory effect of GABA on the CNS by binding to a specific modulating site on 
GABAA-ergic receptors containing 1, 2, 3 or 5 alpha-subunits. Benzodiazepines 
have no affinity for receptor complexes containing 4 or 6 alpha-subunits [47]. 
Activation of specific benzodiazepine receptors by diazepam or other benzodiaz-
epines increase the frequency of GABAA-associated chloride channel opening [48].
The pharmacological activity of valproic acid is expressed in potentiation of 
GABA-ergic neurotransmission and prolongation of the inactivation of voltage-
dependent neuronal sodium channels [49]. Sodium valproate is thought to increase 
brain GABA concentration by the following mechanisms: (1) inhibition of GABA-
transaminase enzyme activity and decreased GABA degradation [50] 2) stimulating 
GAD activity [51] and increasing GABA synthesis; (3) decreased GABA turnover 
[52]. Vigabatrin (gamma-vinyl GABA) is a vinyl-substituted analogue of GABA that 
selectively and irreversibly inhibits the activity of the enzyme GABA-transaminase 
(GABA-T) and significantly increases the concentration of GABA in the brain [53].
After central and systemic administration of diazepam, sodium valproate, 
and vigabatrin dose-dependent decreases of body temperature in rats is observed 
[54–57]. GABA-induced hypothermia has been suggested to be mediated by GABAA 
and/or GABAB receptor activation [58, 59]. The hypothermic effect of sodium val-
proate and vigabatrin occurs later than diazepam-induced hypothermia, which can 
be explained by their indirect mechanism of potentiation of GABA-ergic mediation.
These results are further confirmed in our studies, where we found that 
substances with a GABA-ergic mechanism of action such as diazepam, sodium 
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valproate and vigabatrin effectively reduced the hyperthermic response in experi-
mental serotonin syndrome in rats induced by concomitant administration of 5-HTP 
(100 mg/kg i.p.) - a precursor of serotonin and clorgyline (2 mg/kg i.p.) - selective 
MAO-A inhibitor [14]. The reduction in serotonergic-induced hyperthermia with 
pretreatment of GABA-mimetic drugs is most likely due to an increase in central 
GABA-ergic neurotransmission through activation of GABAA receptors (e.g., diaz-
epam) as well as through indirect action by increasing GABA concentration (e.g., 
sodium valproate, vigabatrin). These results on the hyperthermia associated with 
serotonin syndrome support the hypothesis of an interaction between the GABA-
ergic and serotoninergic systems in thermoregulatory processes.
In our studies, after the concomitant administration of 5-HTP (100 mg/kg i.p.) 
and clorgyline (2 mg/kg i.p.), a model of serotonin syndrome with typical behav-
ioral and autonomic manifestations developed. Tremor occurs 10 minutes after 
injection, the hyperthermic reaction develops at 30 minutes, and the maximum 
value is observed 60 minutes after injection of the substances. All animals in this 
group died between 60 and 90 minutes after injection of serotonin. Pretreatment 
with diazepam at a dose of 5 mg/kg i.p. reduced the hyperthermic reaction at 
30 and 60 min compared to the group with a model of serotonin syndrome, 
in which saline was administered prior to the injection of serotonergic agent. 
Administration of sodium valproate at a dose of 300 mg/kg i.p. reduced the 
hyperthermic reaction at 30 and 60 min compared to the group with a model of 
serotonin syndrome, in which saline was administered before the injection of 
serotonergic substances [56, 60]. Additionally, in another of our experiments, we 
used a modified model of serotonin syndrome induced by the concomitant admin-
istration of fluoxetine (10 mg/kg i.p.) - a selective serotonin reuptake inhibitor 
and clorgyline (2 mg/kg i.p.) - selective MAO-A inhibitor. Vigabatrin at a dose of 
300 mg/kg i.p. significantly decreased the hyperthermic response between 150 
and 300 min in rats with a serotonin syndrome model, compared to the group with 
a model of serotonin syndrome in which only saline was administered before the 
injection of the serotonergic substances [57, 61].
In summary pretreatment with diazepam (5 mg/kg i.p.), sodium valproate 
(300 mg/kg i.p.), and vigabatrin (300 mg/kg i.p.) decreased hyperthermia in 
different experimental models of the serotonin syndrome. These results suggest 
involvement of interactions between GABA-ergic and serotonergic systems in the 
processes of thermoregulation.
We assume that in addition to direct GABA-ergic mechanisms, interactions 
between neurotransmitters or mediator systems are involved in the influence of 
hyperthermia in serotonin syndrome by GABA-ergic substances. Presynaptic 
GABAB receptors affect the release of norepinephrine, dopamine, and 5-hydroxy-
tryptamine [62]. Expression of predominantly GABAB receptors has been found in 
most of the serotonin and catecholamine neurons in the nuclei of the brainstem, 
which are involved in the regulation of autonomic functions [63]. Interactions 
between the GABA-ergic and serotonergic systems are mediated by presynaptic 
heteroreceptor GABAB-inhibition of 5-HT release or by G-protein-coupled inter-
action between 5-HT1A and GABAB-ergic receptors [64].
6.  Effect of 5-HT2-antagonists on experimental models of serotonin 
syndrome
Hyperthermia is the most common cause of complications of life-threatening 
forms of serotonin syndrome in humans and is one of the leading causes of mortality 
reported in experimental models of serotonin syndrome [6, 7].
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As already mentioned, several studies indicate the role of 5-HT2A receptors in 
the development of a hyperthermic response in rats. In this regard, the effect of a 
number of 5-HT2 antagonists in influencing the hyperthermic response in experi-
mental serotonin syndrome has been studied. Some of the serotonin antagonists 
investigated are cyproheptadine, ritanserin, ketanserin, mirtazapine, some anti-
psychotics such as chlorpromazine, risperidone and olanzapine [8, 11–15]. Results 
demonstrate a significant involvement of the 5-HT2A receptors in the development 
of hyperthermic response in experimental serotonin syndrome [65].
Studies have shown that cyproheptadine effectively affects the hyperthermic 
response in an experimental model of serotonin syndrome. Moreover, a com-
parative study demonstrates that, unlike other 5-HT2 antagonists, it prevents 
both the development of serotonin syndrome and the mortality of experimental 
animals [14, 66].
The role of atypical antipsychotics in the treatment of serotonin syndrome has 
been increasingly discussed in the last few years, given that most atypical antipsy-
chotics work primarily by blocking 5-HT2 receptors [67].
Moreover, temperature dysregulation is a documented side effect of antipsy-
chotic drugs [68–72]. That most often manifests in the development of hyper-
thermia, a life-threatening symptom characteristic of the malignant neuroleptic 
syndrome (MNS). Data from various clinical cases, summarized in recent years by 
van Marum [68] and Zonnenberg [69, 70], show that the use of classical or atypical 
antipsychotics carries the risk of developing another, less well-documented adverse 
drug reaction, namely hypothermia. In humans, hypothermia is defined as a body 
temperature below 35 ° C, distinguishing three degrees: mild (33–35 ° C), moderate 
(28–33 ° C) and severe (<28 ° C) hypothermia [69].
Although the hypothermic effect of antipsychotics is less known than the 
hyperthermic one expressed in MNS, analysis of the literature data shows that 
there are almost equal reports of hypothermia (480 cases) and hyperthermia 
(524 cases) associated with the use of antipsychotics. Zonnenberg et al. consider 
that the actual incidence of hypothermia associated with the use of antipsychot-
ics is at least 10 times higher than the documented [69]. For the first time, the 
development of hypothermia after the use of antipsychotic drugs was described 
by Loughnane in a 26-year-old patient on chlorpromazine therapy [73].
The analyzes of van Marum et al. and Zonnenberg et al. indicate that hypo-
thermia most often occurs one week after starting antipsychotic therapy or after 
increasing the dose. They also indicated that the use of atypical antipsychotics 
was more common (approximately 55% of cases), with risperidone being the 
most commonly reported [68, 69, 74]. Mild hypothermia associated with low-dose 
risperidone has also been observed in a child with verbal and physically aggressive 
behavior [75].
Analyzes by van Marum and Zonnenberg show that antipsychotics with a higher 
affinity for blocking 5-HT2A than D2 receptors are more often associated with the 
development of hypothermia [68, 69]. This is also confirmed by experimental and 
clinical studies which demonstrate that the atypical antipsychotics olanzapine and 
risperidone cause a decrease in body temperature indicating that the mechanism of 
hypothermic action is associated with blockade of 5-HT2 receptors [72, 74–76].
7. Conclusion
From all data reported thus far, it can be concluded that 5-HT2 receptors and 
the GABA system are strongly involved in the development of hyperthermia in 
serotonin syndrome and the mortality associated with it.
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Drug-induced hyperthermia is resistant to the action of classical antipyretics 
therefore their use is not recommended. The use of acetylsalicylic acid and other 
classical antipyretics not only has no effect in the case of drug-induced hyperther-
mia but may even cause a worsening of the course of the hyperthermic reaction. In 
our opinion, due to the proven hypothermic effect of the mentioned GABA-ergic 
drugs and 5-HT2-antagonists, their use in the therapeutic regimen of hyperthermia 
in specific hyperthermic syndromes is appropriate.
The similarity in the manifestation of the syndrome in rats and humans can 
serve as a basis for further elucidation of the mechanism of development of sero-
tonin syndrome in humans. The animal model of serotonin syndrome can be used 
to study drugs and drug combinations that pose a potential risk of developing 
serotonin syndrome in humans and the possibilities for its prevention.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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